Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855 [EXTENSION OF 700221438]

Trial Profile

Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855 [EXTENSION OF 700221438]

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Nelonicline (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Adverse reactions
  • Sponsors AbbVie
  • Most Recent Events

    • 27 Oct 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to discontinued.
    • 21 Sep 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 23 Apr 2014 New source identified and integrated (United Kingdom Clinical Research Network: 15207).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top